• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞德西韦。

Remdesivir.

机构信息

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia; Department of Chemistry, Faculty of Science and Technology, Al-Neelain University, Khartoum, Sudan.

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

出版信息

Profiles Drug Subst Excip Relat Methodol. 2023;48:71-108. doi: 10.1016/bs.podrm.2022.11.003. Epub 2023 Feb 9.

DOI:10.1016/bs.podrm.2022.11.003
PMID:37061276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9910426/
Abstract

Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.

摘要

瑞德西韦，商品名为 Veklury，是一种具有广谱活性的抗病毒药物。在大流行期间，有许多国家批准将瑞德西韦用于治疗 COVID-19。瑞德西韦最初是为治疗丙型肝炎而设计的，但后来也对其进行了埃博拉病毒病和马尔堡病毒感染的测试。瑞德西韦是一种前药，旨在促进 GS-441524 单磷酸盐的细胞内转运及其随后转化为 GS-441524 三磷酸盐，这是一种核苷酸类似物抑制剂，可抑制病毒 RNA 聚合酶。本章的目的是对瑞德西韦（GS-5734）进行全面综述，包括其命名、理化性质、制备方法、鉴定程序、许多定性和定量分析技术、ADME 概况和药理学作用。此外，本章还提供了各种色谱和光谱技术，用于分离复方制剂中的溴莫尼定和其他药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/8d1b36233210/f03-09-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/938a7b8f11f0/f03-01-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/ba057a7baa81/sch03-01-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/6941d8c132e8/sch03-02-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/47199da7e167/sch03-03-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/4ab5ef2bf875/f03-02-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/300c1982d8a2/f03-03-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/48b3fdf084e5/f03-04-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/085654b60a68/f03-05-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/6cc4b4e2fd26/f03-06-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/fd15d06da494/f03-07-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/96e731a905d4/f03-08-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/8d1b36233210/f03-09-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/938a7b8f11f0/f03-01-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/ba057a7baa81/sch03-01-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/6941d8c132e8/sch03-02-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/47199da7e167/sch03-03-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/4ab5ef2bf875/f03-02-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/300c1982d8a2/f03-03-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/48b3fdf084e5/f03-04-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/085654b60a68/f03-05-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/6cc4b4e2fd26/f03-06-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/fd15d06da494/f03-07-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/96e731a905d4/f03-08-9780443193828_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a624/9910426/8d1b36233210/f03-09-9780443193828_lrg.jpg

相似文献

1
Remdesivir.瑞德西韦。
Profiles Drug Subst Excip Relat Methodol. 2023;48:71-108. doi: 10.1016/bs.podrm.2022.11.003. Epub 2023 Feb 9.
2
Broad-Spectrum Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524).ODBG-P-RVn 广谱抗病毒活性：一种口服可利用的、脂修饰的瑞德西韦前药单磷酸酯（GS-441524）。
Microbiol Spectr. 2021 Dec 22;9(3):e0153721. doi: 10.1128/Spectrum.01537-21. Epub 2021 Nov 24.
3
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.建立并验证 UHPLC-MS/MS 法测定前药瑞德西韦及其代谢产物 GS-441524 的浓度：一种用于 SARS-CoV-2/COVID-19 和埃博拉病毒病临床药代动力学的工具。
J Antimicrob Chemother. 2020 Jul 1;75(7):1772-1777. doi: 10.1093/jac/dkaa152.
4
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.瑞德西韦：一种有前景的 COVID-19 大流行抗病毒候选药物：小型综述。
Eur J Med Chem. 2020 Sep 1;201:112527. doi: 10.1016/j.ejmech.2020.112527. Epub 2020 Jun 6.
5
A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.瑞德西韦综述：一种有望用于治疗新冠肺炎的药物
Drug Des Devel Ther. 2020 Aug 6;14:3215-3222. doi: 10.2147/DDDT.S261154. eCollection 2020.
6
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.瑞德西韦的药代动力学、药效学和药物相互作用特征：一种 SARS-CoV-2 复制抑制剂。
Clin Pharmacokinet. 2021 May;60(5):569-583. doi: 10.1007/s40262-021-00984-5. Epub 2021 Mar 30.
7
Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.瑞德西韦：从埃博拉病毒病到 COVID-19 的希望之光。
Rev Med Virol. 2020 Nov;30(6):1-13. doi: 10.1002/rmv.2133. Epub 2020 Jul 30.
8
Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.瑞德西韦（GS-5734）在 COVID-19 治疗中的第四次机会。
Curr Drug Targets. 2021;22(12):1346-1356. doi: 10.2174/1389450121999201202110303.
9
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.瑞德西韦和 GS-441524 对德尔塔、奥密克戎和其他新兴的 SARS-CoV-2 变体保持抗病毒活性。
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0022222. doi: 10.1128/aac.00222-22. Epub 2022 May 9.
10
The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections.广谱抗病毒医疗对策的发展，以治疗由自然或武器化病毒感染引起的病毒性出血热。
PLoS Negl Trop Dis. 2022 Mar 8;16(3):e0010220. doi: 10.1371/journal.pntd.0010220. eCollection 2022 Mar.

引用本文的文献

1
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.有症状的新冠门诊患者抗病毒治疗的疗效和安全性：网状Meta分析和预算影响分析
Front Pharmacol. 2025 Apr 16;16:1537018. doi: 10.3389/fphar.2025.1537018. eCollection 2025.
2
Unlocking the potential of remdesivir: innovative approaches to drug delivery.释放瑞德西韦的潜力：药物递送的创新方法。
Drug Deliv Transl Res. 2025 Apr 17. doi: 10.1007/s13346-025-01843-7.
3
Primary Pyrrolimines and Pyridinimines.伯吡咯啉和吡啶亚胺。

本文引用的文献

1
Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir.利用连续流动化学开发大规模氰化工艺用于瑞德西韦的合成。
Org Process Res Dev. 2020 May 21;24(10):2113-2121. doi: 10.1021/acs.oprd.0c00172. eCollection 2020 Oct 16.
2
Selecting a stable solid form of remdesivir using microcrystal electron diffraction and crystal structure prediction.利用微晶电子衍射和晶体结构预测选择瑞德西韦的稳定固态形式。
RSC Adv. 2021 May 12;11(28):17408-17412. doi: 10.1039/d1ra03100g. eCollection 2021 May 6.
3
Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs "Remdesivir and Favipiravir": Green assessment with application to pharmaceutical formulations and human plasma.
Molecules. 2025 Mar 10;30(6):1239. doi: 10.3390/molecules30061239.
4
Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies.埃博拉病毒病的治疗：从血清疗法到单克隆抗体的应用。
Antibodies (Basel). 2025 Mar 5;14(1):22. doi: 10.3390/antib14010022.
5
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection.双重抗病毒疗法对长期感染SARS-CoV-2的免疫抑制患者的有效性和耐受性
Infect Dis Rep. 2025 Feb 26;17(2):17. doi: 10.3390/idr17020017.
6
Evidence-Based Guidance for One Health Preparedness, Prevention, and Response Strategies to Marburg Virus Disease Outbreaks.针对马尔堡病毒病疫情的“同一健康”防范、预防及应对策略的循证指南。
Diseases. 2024 Dec 2;12(12):309. doi: 10.3390/diseases12120309.
7
Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.意大利两家转诊医院中使用瑞德西韦治疗新冠肺炎住院患者的真实生活经验：一项倾向评分匹配分析
Sci Rep. 2024 Apr 23;14(1):9303. doi: 10.1038/s41598-024-59957-w.
8
Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches.探索埃博拉病毒感染治疗的复杂领域：新兴药理学方法综述
Infect Dis Ther. 2024 Jan;13(1):21-55. doi: 10.1007/s40121-023-00913-y. Epub 2024 Jan 19.
9
A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains.一种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒（包括所有主要奥密克戎毒株）的强效广谱中和纳米抗体。
MedComm (2020). 2023 Oct 26;4(6):e397. doi: 10.1002/mco2.397. eCollection 2023 Dec.
用于测定抗冠状病毒药物“瑞德西韦和法匹拉韦”的新型环保薄层色谱-密度测定法：应用于药物制剂和人体血浆的绿色评估
Microchem J. 2022 Mar;174:107101. doi: 10.1016/j.microc.2021.107101. Epub 2021 Dec 18.
4
Total synthesis of remdesivir.瑞德西韦的全合成。
Tetrahedron Lett. 2022 Jan 5;88:153590. doi: 10.1016/j.tetlet.2021.153590. Epub 2021 Dec 9.
5
Aggregation versus inclusion complexes to solubilize drugs with cyclodextrins. A case study using sulphobutylether-β-cyclodextrins and remdesivir.用于用环糊精增溶药物的聚集物与包合物。以磺丁基醚-β-环糊精和瑞德西韦为例的案例研究。
J Mol Liq. 2021 Dec 1;343:117588. doi: 10.1016/j.molliq.2021.117588. Epub 2021 Sep 17.
6
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential.瑞德西韦的吸收、分布、代谢、排泄及药代动力学特性：其药物相互作用潜力
Pharmaceuticals (Basel). 2021 Jul 8;14(7):655. doi: 10.3390/ph14070655.
7
Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis.瑞德西韦治疗住院 COVID-19 患者的疗效和安全性：系统评价和荟萃分析。
Infection. 2022 Feb;50(1):27-41. doi: 10.1007/s15010-021-01671-0. Epub 2021 Jul 31.
8
Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat.定量高效液相色谱-串联质谱法测定瑞德西韦的活性代谢产物 Nuc 在大鼠体内的药代动力学。
Anal Bioanal Chem. 2021 Sep;413(23):5811-5820. doi: 10.1007/s00216-021-03561-8. Epub 2021 Jul 24.
9
Accelerated stability study of the ester prodrug remdesivir: Recently FDA-approved Covid-19 antiviral using reversed-phase-HPLC with fluorimetric and diode array detection.酯前药瑞德西韦的稳定性加速研究：最近 FDA 批准的用于治疗 COVID-19 的抗病毒药物，采用反相高效液相色谱法，荧光和二极管阵列检测。
Biomed Chromatogr. 2021 Dec;35(12):e5212. doi: 10.1002/bmc.5212. Epub 2021 Aug 9.
10
Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma.绿色敏感的荧光光度法测定瑞德西韦，一种获得 FDA 批准的 SARS-CoV-2 候选抗病毒药物；在药物制剂和加标人血浆中的应用。
Anal Methods. 2021 Jun 21;13(23):2596-2602. doi: 10.1039/d1ay00469g. Epub 2021 May 21.